Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

The NetherlandsBack to the Netherlands

Clinical trials in Breda – page 21

1 243 clinical trials in Breda, The Netherlands across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

The NetherlandsOur site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
Breda at a glance
1 243
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 243 trials in Breda

Open in trial search

Acute myeloid leukaemia

Recruiting

Study on Ivosidenib, Azacitidine, and Venetoclax for Adults with Newly Diagnosed IDH1-Mutated Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Myelodysplastic syndrome

Recruiting

Study on the Effectiveness of Lisaftoclax and Azacitidine in Adults with Newly Diagnosed Higher Risk Myelodysplastic Syndrome

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Ascentage Pharma Group Inc.

Peritoneal mesothelioma malignant

Recruiting

Study on Nivolumab and MesoPher for Patients with Peritoneal Mesothelioma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Adult T-cell lymphoma/leukaemia refractory

Recruiting

Study Comparing Duvelisib with Gemcitabine or Bendamustine for Patients with Relapsed or Resistant T Cell Lymphoma Originating from T Follicular Helper Cells

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Duvelisib
  • Sponsor:Secura Bio Limited

Dementia

Recruiting

Title: Evaluation of lorazepam, pregabalin, and olanzapine in treating agitated behavior in dementia patients who did not respond to standard treatments

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:65+ years
  • Substances:Lorazepam
  • Sponsor:Amsterdam UMC Stichting

Thyroid cancer

Recruiting

Study on [18F]Tetrafluoroborate PET/CT for Detecting Thyroid Cancer in Patients with Differentiated Thyroid Cancer

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Tetrafluoroborate ION F-18
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Cardiac arrest+3

Recruiting

Study of anti-seizure drug combination in comatose patients with status epilepticus after cardiac arrest

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Diazepam
  • Sponsor:Universiteit Twente

Chronic lymphocytic leukaemia+1

Recruiting

Study on Venetoclax, Obinutuzumab, and Pirtobrutinib for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:University Of Cologne

Colorectal cancer

Recruiting

Study Comparing Amivantamab and Drug Combination for Patients with Recurrent or Metastatic Colorectal Cancer Without KRAS/NRAS and BRAF Mutations

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Janssen Cilag International

Rectal cancer

Recruiting

Study Comparing Surgery and Chemoradiotherapy with Capecitabine for Early Rectal Cancer Patients

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Amsterdam UMC Stichting

Sickle cell disease

Recruiting

Study on How Well Etavopivat Works for Adolescents and Adults with Sickle Cell Disease

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Etavopivat
  • Sponsor:Novo Nordisk A/S

Triple negative breast cancer

Recruiting

Study on Pembrolizumab for Patients with Early Triple-Negative Breast Cancer Responding Well to Initial Treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Unicancer

Other cities in the Netherlands

The busiest research cities in the country

All 101 cities in the Netherlands

Clinical research in Breda

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on multiple myeloma, breast cancer, and leukemia treatments. Studies evaluate novel drug combinations and targeted therapies to improve patient outcomes.

  • Advanced/Metastatic Breast Cancer Treatment
  • Novel Therapies for AML
  • Melanoma Treatment Optimization

Investigations include combination therapies and treatment discontinuation strategies for various cancer types.

02 Cardiovascular Studies

Research focusing on coronary artery disease and post-procedural care, including innovative diagnostic techniques and antithrombotic strategies.

  • Advanced Imaging Technologies
  • Post-TAVI Treatment Protocols
  • Stroke Prevention Strategies

Emphasis on personalized treatment approaches and diagnostic accuracy improvement.

03 Respiratory Medicine

Clinical trials examining respiratory infections and chronic conditions, including vaccine development and asthma management strategies.

  • RSV Vaccine Studies
  • Asthma Treatment Innovation
  • Lung Cancer Therapies

Focus on both preventive measures and treatment optimizations for respiratory conditions.

Back to the NetherlandsAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.